GENKYOTEX’S GKT831 PREVENTS MULTIPLE COMPLICATIONS OF PORTAL HYPERTENSION IN PRECLINICAL MODEL
DATA SUPPORTS THERAPEUTIC ROLE OF GKT831 IN ADVANCED LIVER FIBROSIS
- Results published in Clinics and Research in Hepatology and Gastroenterology
- Phase 3 trial being planned in primary biliary cholangitis
Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), the leading biopharmaceutical company in NOX therapies, today announced the publication of data in Clinics and Research in Hepatology and Gastroenterology showing that its anti-fibrotic drug candidate GKT831, prevents multiple complications of portal hypertension in a preclinical model.
For more Information,